Life sciences

In life sciences, capital investments are directly tied to business outcomes, bringing new therapies to  market, scaling capacity, and maintaining compliance across global facilities. As products progress through the R&D pipeline, organizations must continuously align facility readiness, capacity investments, and compliance requirements to address shifting priorities.

In many organizations, capital decisions are still made across disconnected teams and systems, without a unified view of pipeline priorities, funding constraints, and execution readiness. As a result, capital is committed too early or too rigidly, facility readiness falls behind clinical timelines, and changes in trial outcomes or regulatory requirements lead to costly rework, revalidation, and delays. Without a shared view across planning, finance, and delivery teams, it becomes difficult to evaluate trade-offs or adapt quickly.

Aurigo brings structure to this complexity by connecting capital planning, financial visibility, and execution governance in a single system of record. It enables life sciences teams to plan, fund, and deliver facility investments while staying aligned to evolving pipeline priorities. Intelligence works directly within workflows to surface insights faster, identify risks earlier, and keep execution on track, while maintaining control, compliance, and auditability.

Aurigo Primus extends this further by enabling continuous planning, prioritization, and adaptation of capital decisions as conditions evolve. By connecting pipeline signals, capacity planning, financial constraints, and regulatory requirements in one platform, Primus provides real-time visibility into trade-offs, scenario impacts, and downstream effects, so capital execution stays aligned to commercialization timelines and delivers measurable business value.